Sugi Predict

Sugi Predict / Targets / TP53BP1

TP53BP1

TP53-binding protein 1 · Q12888 · TP53BP1 on Sugi Atlas →

8,153 patent compounds predicted against TP53BP1, 4,966 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL945906 SCHEMBL945906 0.51 14/20
SCHEMBL945253 SCHEMBL945253 0.42 8/20
SCHEMBL934467 SCHEMBL934467 0.43 7/20
SCHEMBL944445 SCHEMBL944445 0.39 6/20
SCHEMBL1083716 SCHEMBL1083716 0.52 5/20
SCHEMBL1698726 SCHEMBL1698726 0.51 5/20
SCHEMBL310733 SCHEMBL310733 0.50 5/20
SCHEMBL1083690 SCHEMBL1083690 0.49 5/20
SCHEMBL1858169 SCHEMBL1858169 0.47 5/20
SCHEMBL1085050 SCHEMBL1085050 0.68 4/20
SCHEMBL1085344 SCHEMBL1085344 0.64 4/20
SCHEMBL1085239 SCHEMBL1085239 0.60 4/20
SCHEMBL77669 SCHEMBL77669 0.56 4/20
SCHEMBL1085504 SCHEMBL1085504 0.56 4/20
SCHEMBL1085624 SCHEMBL1085624 0.56 4/20
SCHEMBL284884 SCHEMBL284884 0.51 4/20
SCHEMBL723415 SCHEMBL723415 0.51 4/20
SCHEMBL310306 SCHEMBL310306 0.49 4/20
SCHEMBL284764 SCHEMBL284764 0.48 4/20
SCHEMBL310165 SCHEMBL310165 0.47 4/20

Clinical trials — most relevant to TP53BP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PHASE3ACTIVE_NOT_RECRUITING
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease PHASE2RECRUITING
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation PHASE2UNKNOWN
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer PHASE2RECRUITING
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML PHASE2COMPLETED
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer PHASE1/PHASE2COMPLETED
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma PHASE1/PHASE2COMPLETED
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer PHASE2COMPLETED
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery PHASE2RECRUITING
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma PHASE2COMPLETED
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy PHASE2COMPLETED
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer PHASE2ACTIVE_NOT_RECRUITING
Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL PHASE2NOT_YET_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies PHASE1COMPLETED
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS PHASE1UNKNOWN
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors PHASE1SUSPENDED
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer nanNOT_YET_RECRUITING
Unusual Infiltrative Patterns of Malignant Cells in Endometrial Carcinoma and Immunohistochemical Expression of P53 nanUNKNOWN
Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation nanRECRUITING
International Pediatric Adrenocortical Tumor Registry nanRECRUITING
Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy nanWITHDRAWN
Sub-type Specific Genomic Mutations in sBOTs nanACTIVE_NOT_RECRUITING
Advanced Refractory Solid Tumors With TP53 Mutations Register Study nanUNKNOWN
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility nanRECRUITING
Li-Fraumeni Syndrome/TP53 Biobank nanRECRUITING
Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome nanCOMPLETED
Biomarker Monitoring in TP53 Mutation Carriers nanCOMPLETED
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TP53BP1 binder may also engage these)

ProteinNameSimilarity
P70399 — 0.998 P70399 →
Q28DZ0 — 0.992 Q28DZ0 →
RTN4 Reticulon-4 0.991 landscape →
Q99P72 — 0.990 Q99P72 →
Q9ULD2 — 0.988 Q9ULD2 →
Q9JIX8 — 0.988 Q9JIX8 →
Q14B71 — 0.988 Q14B71 →
Q8C4A5 — 0.988 Q8C4A5 →
Q9UKL3 — 0.988 Q9UKL3 →
Q9JK11 — 0.988 Q9JK11 →
CDCA2 Cell division cycle-associated protein 2 0.988 landscape →
Q3V0A6 — 0.988 Q3V0A6 →
O94854 — 0.988 O94854 →
Q5DTW7 — 0.987 Q5DTW7 →
Q9WUF3 — 0.987 Q9WUF3 →
Q4V7J0 — 0.987 Q4V7J0 →
Q9Y2F5 — 0.987 Q9Y2F5 →
O88466 — 0.987 O88466 →
Q6NWJ0 — 0.987 Q6NWJ0 →
Q5VV67 — 0.987 Q5VV67 →
Q5VWN6 — 0.987 Q5VWN6 →
ASH1L Histone-lysine N-methyltransferase ASH1L 0.987 landscape →
Q6DIA7 — 0.987 Q6DIA7 →
E1BC15 — 0.987 E1BC15 →
M0RD54 — 0.987 M0RD54 →
MKI67 Proliferation marker protein Ki-67 0.987 landscape →
A4IGL8 — 0.987 A4IGL8 →
Q3T0A6 — 0.987 Q3T0A6 →
Q80U44 — 0.987 Q80U44 →
O35923 — 0.987 O35923 →